【佳學基因檢測】ADRA1A等位基因突變會增加疾病的風險嗎？

基因檢測的序列名稱：

ADRA1A

人體基因序列變化與疾病表征數(shù)據(jù)庫中的基因代碼：

148

人體基因序列數(shù)據(jù)庫中國際交流名稱全稱

adrenoceptor alpha 1A

中國數(shù)據(jù)庫中基因全稱：腎上腺素受體1A基因檢測報告英文版基因簡介

Alpha-1-adrenergic receptors (alpha-1-ARs) are members of the G protein-coupled receptor superfamily. They activate mitogenic responses and regulate growth and proliferation of many cells. There are 3 alpha-1-AR subtypes: alpha-1A, -1B and -1D, all of which signal through the Gq/11 family of G-proteins and different subtypes show different patterns of activation. This gene encodes alpha-1A-adrenergic receptor. Alternative splicing of this gene generates four transcript variants, which encode four different isoforms with distinct C-termini but having similar ligand binding properties. [provided by RefSeq, Jul 2008]

基因突變所影響的基因信息

Alpha-1-腎上腺素受體（alpha-1-ARs）是G蛋白偶聯(lián)受體超家族的成員。它們激活有絲分裂反應(yīng)并調(diào)節(jié)許多細胞的生長和增殖。存在3種alpha-1-AR亞型：alpha-1A，-1B和-1D，它們均通過G蛋白的Gq / 11家族發(fā)出信號，不同的亞型顯示出不同的激活模式。該基因編碼α-1A-腎上腺素能受體。該基因的可變剪接產(chǎn)生四個轉(zhuǎn)錄物變體，其編碼具有不同的C末端但具有相似的配體結(jié)合特性的四個不同的同工型。[由RefSeq提供，2008年7月]

國際國內(nèi)該堿基因序列的其他英語文字母簡稱：

ADRA1C, ADRA1L1, ALPHA1AAR

基因解碼對該基因序列在細胞核中的染色體所給予的編號：

該基因序列位于人類第8號染色體上。

基因解碼對基因序列的正確定位

該基因序列在GRCh37版本中的起始位置坐標為：26605667；結(jié)束位置坐標為：26727003。該基因序列在GRCh38版本中的起始位置坐標為：26738113；結(jié)束位置坐標為：26870994。正確的基因信息定位是基因檢測和對檢測結(jié)果進行正確解讀的關(guān)鍵。

佳學基因解碼對該基因的功能分類：國際版

G-protein coupled receptors/GPCRs excl olfactory receptors

基因解碼對該基因的功能分類：中文版

G 蛋白偶聯(lián)受體/GPCR 不包括嗅覺受體

結(jié)構(gòu)與功能基因解碼所揭示的該基因在細胞內(nèi)發(fā)揮作用的場所（國際版）：

正在通過基因解碼技術(shù)進行收集、查證并編輯，請關(guān)注佳學基因，獲得及明更新的人類基因序列變化與疾病表征數(shù)據(jù)庫的更新內(nèi)容

結(jié)構(gòu)與功能基因解碼所揭示的該基因發(fā)揮作用的細胞內(nèi)位置（中文版）：

正在通過基因解碼技術(shù)進行收集、查證并編輯，請關(guān)注佳學基因，獲得及明更新的人類基因序列變化與疾病表征數(shù)據(jù)庫的更新內(nèi)容

該基因序列變化后增加的疾病風險（國際版）：

Ventricular Remodeling; Cannabis Dependence; cocaine use; Cocaine Abuse; Cocaine Dependence; Diabetes Mellitus, Experimental; Liver Cirrhosis; Unipolar Depression; Major Depressive Disorder; Bipolar Disorder; Schizophrenia

如果該基因突變后，風險可能增加的疾病類型（中文版）：

心室重塑；大麻依賴；使用可卡因；可卡因濫用；可卡因依賴；糖尿病實驗性的；肝硬化；單極抑郁癥；嚴重抑郁癥;躁郁癥;精神分裂癥

GWAS基因檢測所建立的與該基因的疾病關(guān)聯(lián)（國際版）：

正在通過基因解碼技術(shù)進行收集、查證并編輯，請關(guān)注佳學基因，獲得及明更新的人類基因序列變化與疾病表征數(shù)據(jù)庫的更新內(nèi)容

GWAS基因檢測所解碼的該基因突變會增加風險的疾病種類（中文版）：

正在通過基因解碼技術(shù)進行收集、查證并編輯，請關(guān)注佳學基因，獲得及明更新的人類基因序列變化與疾病表征數(shù)據(jù)庫的更新內(nèi)容

以該基因做靶點的藥物（國際版）：

Amphetamine (Protein heterodimerization activity);Midodrine (Protein heterodimerization activity);Citalopram (Protein heterodimerization activity);Ziprasidone (Protein heterodimerization activity);Cabergoline (Protein heterodimerization activity);Dapiprazole (Protein heterodimerization activity);Amitriptyline (Protein heterodimerization activity);Olanzapine (Protein heterodimerization activity);Alfuzosin (Protein heterodimerization activity);Clozapine (Protein heterodimerization activity);Norepinephrine (Protein heterodimerization activity);Mirtazapine (Protein heterodimerization activity);Mirtazapine (Protein heterodimerization activity);Phenylephrine (Protein heterodimerization activity);Phenylpropanolamine (Protein heterodimerization activity);Loxapine (Protein heterodimerization activity);Promazine (Protein heterodimerization activity);Dipivefrin (Protein heterodimerization activity);Droperidol (Protein heterodimerization activity);Prazosin (Protein heterodimerization activity);Imipramine (Protein heterodimerization activity);Chlorpromazine (Protein heterodimerization activity);Chlorpromazine (Protein heterodimerization activity);Nortriptyline (Protein heterodimerization activity);Amoxapine (Protein heterodimerization activity);Amoxapine (Protein heterodimerization activity);Clonidine (Protein heterodimerization activity);Doxazosin (Protein heterodimerization activity);Labetalol (Protein heterodimerization activity);Metaraminol (Protein heterodimerization activity);Nicardipine (Protein heterodimerization activity);Trazodone (Protein heterodimerization activity);Epinephrine (Protein heterodimerization activity);Thioridazine (Protein heterodimerization activity);Phentolamine (Protein heterodimerization activity);Ergotamine (Protein heterodimerization activity);Nicergoline (Protein heterodimerization activity);Tamsulosin (Protein heterodimerization activity);Methoxamine (Protein heterodimerization activity);Trimipramine (Protein heterodimerization activity);Risperidone (Protein heterodimerization activity);Epinastine (Protein heterodimerization activity);Propiomazine (Protein heterodimerization activity);Tolazoline (Protein heterodimerization activity);Fenoldopam (Protein heterodimerization activity);Trifluoperazine (Protein heterodimerization activity);Pseudoephedrine (Protein heterodimerization activity);Benzphetamine (Protein heterodimerization activity);Flupentixol (Protein heterodimerization activity);Phenoxybenzamine (Protein heterodimerization activity);Maprotiline (Protein heterodimerization activity);Oxymetazoline (Protein heterodimerization activity);Apraclonidine (Protein heterodimerization activity);Ergoloid mesylate (Protein heterodimerization activity);Promethazine (Protein heterodimerization activity);Carvedilol (Protein heterodimerization activity);Doxepin (Protein heterodimerization activity);Nefazodone (Protein heterodimerization activity);Desipramine (Protein heterodimerization activity);Terazosin (Protein heterodimerization activity);Escitalopram (Protein heterodimerization activity);Pergolide (Protein heterodimerization activity);Bromocriptine (Protein heterodimerization activity);Quetiapine (Protein heterodimerization activity);Aripiprazole (Protein heterodimerization activity);Ergonovine (Protein heterodimerization activity);Paliperidone (Protein heterodimerization activity);Bevantolol (Protein heterodimerization activity);Ephedrine (Protein heterodimerization activity);Mephentermine (Protein heterodimerization activity);Methotrimeprazine (Protein heterodimerization activity);4-Methoxyamphetamine (Protein heterodimerization activity);Dextroamphetamine (Protein heterodimerization activity);Phendimetrazine (Protein heterodimerization activity);Acepromazine (Protein heterodimerization activity);Thioproperazine (Protein heterodimerization activity);Zuclopenthixol (Protein heterodimerization activity);Dronedarone (Protein heterodimerization activity);Iloperidone (Protein heterodimerization activity);R450 (Protein heterodimerization activity);Epicept NP-1 (Protein heterodimerization activity);Sertindole (Protein heterodimerization activity);Mianserin (Protein heterodimerization activity);Silodosin (Protein heterodimerization activity);Asenapine (Protein heterodimerization activity);Droxidopa (Protein heterodimerization activity);Xylometazoline (Protein heterodimerization activity);Isometheptene (Protein heterodimerization activity);Levonordefrin (Protein heterodimerization activity);Naphazoline (Protein heterodimerization activity);Tetryzoline (Protein heterodimerization activity);Cirazoline (Protein heterodimerization activity)

針對該基因所產(chǎn)生的突變，可能有正確效果的藥物（中文版）：

苯丙胺（蛋白質(zhì)異二聚活性）；米多君（蛋白質(zhì)異二聚活性）；西酞普蘭（蛋白質(zhì)異二聚活性）；齊拉西酮（蛋白質(zhì)異二聚活性）；卡麥角林（蛋白質(zhì)異二聚活性）；達哌唑（蛋白質(zhì)異二聚活性）；阿米替林（蛋白質(zhì)異二聚活性）；奧氮平(蛋白質(zhì)異二聚活性);阿夫唑嗪(蛋白質(zhì)異二聚活性);氯氮平(蛋白質(zhì)異二聚活性);去甲腎上腺素(蛋白質(zhì)異二聚活性);米氮平(蛋白質(zhì)異二聚活性);米氮平(蛋白質(zhì)異二聚活性);苯腎上腺素(蛋白質(zhì)異二聚活性);苯丙醇胺(蛋白質(zhì)異二聚活性);洛沙平(蛋白質(zhì)異二聚活性);異丙嗪(蛋白質(zhì)異二聚活性);地匹福林(蛋白質(zhì)異二聚活性);氟哌利多(蛋白質(zhì)異二聚活性);哌唑嗪(蛋白質(zhì)異二聚活性);丙咪嗪(蛋白質(zhì)異二聚活性);氯丙嗪(蛋白質(zhì)異二聚活性)異二聚活性);氯丙嗪(蛋白質(zhì)異二聚活性);去甲替林(蛋白質(zhì)異二聚活性);阿莫沙平(蛋白質(zhì)異二聚活性);阿莫沙平(蛋白質(zhì)異二聚活性);可樂定(蛋白質(zhì)異二聚活性);多沙唑嗪(蛋白質(zhì)異二聚活性);拉貝洛爾(蛋白質(zhì)異二聚活性)活性);間羥胺(蛋白質(zhì)異二聚活性);尼卡地平(蛋白質(zhì)異二聚活性);曲唑酮(蛋白質(zhì)異二聚活性);腎上腺素(蛋白質(zhì)異二聚活性);硫利達嗪(蛋白質(zhì)異二聚活性);酚妥拉明(蛋白質(zhì)異二聚活性);麥角胺(蛋白質(zhì)異二聚活性) );尼麥角林(蛋白質(zhì)異二聚活性);坦索羅辛(蛋白質(zhì)異二聚活性);甲氧明(蛋白質(zhì)異二聚活性);曲米帕明(蛋白質(zhì)異二聚活性);利培酮(蛋白質(zhì)異二聚活性);依匹斯汀(蛋白質(zhì)異二聚活性);丙哌嗪(蛋白質(zhì)異二聚活性) ;托拉唑啉（蛋白質(zhì)異二聚活性）；非諾多泮（蛋白質(zhì)異二聚活性）；三氟拉嗪（蛋白質(zhì)異二聚活性）；偽麻黃堿（蛋白質(zhì)異二聚活性）；苯丙胺（蛋白質(zhì)異二聚活性）；氟哌噻噸（蛋白質(zhì)異二聚活性）；苯氧芐胺（蛋白質(zhì)異二聚活性）；馬普替林（蛋白質(zhì)異二聚化活性）；羥甲唑啉（蛋白質(zhì)異二聚化活性）；安可樂定（蛋白質(zhì)異二聚化活性）；麥角林甲磺酸鹽（蛋白質(zhì)異二聚化活性）；異丙嗪（蛋白質(zhì)異二聚化活性）；卡維地洛（蛋白質(zhì)異二聚化活性）；多慮平（蛋白質(zhì)異二聚化活性）；奈法唑酮(蛋白質(zhì)異二聚活性);地昔帕明(蛋白質(zhì)異二聚活性);特拉唑嗪(蛋白質(zhì)異二聚活性);艾司西酞普蘭(蛋白質(zhì)異二聚活性);培高利特(蛋白質(zhì)異二聚活性);溴隱亭(蛋白質(zhì)異二聚活性);喹硫平(蛋白質(zhì)異二聚活性);阿立哌唑(蛋白質(zhì)異二聚活性);麥角新堿(蛋白質(zhì)異二聚活性);帕利哌酮(蛋白質(zhì)異二聚活性);貝伐洛爾(蛋白質(zhì)異二聚活性);麻黃堿(蛋白質(zhì)異二聚活性);美芬特明(蛋白質(zhì)異二聚活性);甲氧美拉嗪(蛋白質(zhì)異二聚活性);4-甲氧苯丙胺(蛋白質(zhì)異二聚活性);右旋苯丙胺(蛋白質(zhì)異二聚活性);苯二甲曲嗪(蛋白質(zhì)異二聚活性);乙酰丙嗪(蛋白質(zhì)異二聚活性);硫丙哌嗪(蛋白質(zhì)異二聚活性);珠氯噻醇(蛋白質(zhì)異二聚活性);決奈達隆(蛋白質(zhì)異二聚活性);伊潘立酮(蛋白質(zhì)異二聚活性);R450(蛋白質(zhì)異二聚活性);Epicept NP-1(蛋白質(zhì)異二聚活性);Sertindole(蛋白質(zhì)異二聚活性);米安色林(蛋白質(zhì)異二聚活性);西洛多辛(蛋白質(zhì)異二聚活性);阿塞那平(蛋白質(zhì)異二聚活性) ;屈昔多巴（蛋白質(zhì)異二聚化活性）;賽洛唑啉（蛋白質(zhì)異二聚化活性）;異美?。ǖ鞍踪|(zhì)異二聚化活性）;左旋諾德福林（蛋白質(zhì)異二聚化活性）;萘甲唑啉（蛋白質(zhì)異二聚化活性）;Tetryzoline（蛋白質(zhì)異二聚化活性）;西拉唑啉（蛋白質(zhì)異二聚化活性）